drugset / Trial / NCT02447016
Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this prospective, open label study is to check for differences in neuropsychiatric and neurocognitive measurements among patients that will be switched from Atripla to Eviplera among 40 patients.
Timeline
- Start
- 2015-05
- Primary completion
- 2016-12-21
- Completion
- 2016-12-21
Outcome
Outcome not reported
Stopped: “no more participants taking atripla”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Efavirenz | Other / unclassified | — | — |
| Subject | Rilpivirine | Small molecule | — | — |
| Subject | Tenofovir disoproxil fumarate | Small molecule | — | — |
| Subject | emtricitabine | Other / unclassified | — | — |